High levels of Cyclin E in the nucleus have been reported to occur at an early stage in development of breast cancer [153], and low molecular weight forms of cyclin E are thought to be responsible for hyperactivation of CDK2 in breast cancer, melanoma and ovarian carcinoma [130,232,233,235,236,237,238]. Here, CDK2 is linked to melanoma.